hVIVO making significant number of poster presentations at influenza conference, Options IX, along with exhibition presence, Chicago USA, August 2016July 26, 2016 10:48 am
Options IX for the Control of Influenza, 24 – 28 August 2016, Sheraton Grand Chicago, Chicago, USA
No less than four poster presentations addressing key issues such as immunity development, vaccinating older populations, differential infectivity and volunteer screening using the hVIVO platform are scheduled for presentation by hVIVO experts at the prestigious Options IX for the Control of Influenza event. The event organised by the International Society for Influenza and Other Respiratory Virus Diseases (ISIRV), will be taking place in August 2016 in Chicago. hVIVO will also be exhibiting throughout the event (Booth #423).
‘Options IX’ is the premier conference designed for leading virologists, infectious diseases, pulmonary/critical care specialist and other clinicians, scientists, public health and epidemiology researchers and specialists, health care policy makers and government and non-government agency staff. It is expected to receive around 1,500 experts in these fields over the 5-day conference schedule.
The event intends to provide comprehensive, state-of-the art scientific information for all disciplines involved in influenza prevention, control, and treatment, including seasonal and pandemic planning, as well as providing opportunities for informal discussions and information exchange in a collegial atmosphere.
The hVIVO Poster Sessions all take place on Saturday, 27 August in Exhibition Halls A&B with poster titles and individual presenters detailed below:
“The Human Viral Influenza Challenge Model: The Relationship between Infection Rates, Virus Shedding, Symptoms, Pyrexia and Pre-existing Humoral and Cellular Immunity.” Dr. Anthony Gilbert, hVIVO Medical Director (Publication/Poster Board Number: LBP-31)
“Human influenza challenge of an older population (45 to 65 years of age).” Dr. Nicolas Noulin, hVIVO Principal Virologist (Publication/Poster Board Number: LBP-30)
“Use of allele specific RT-qPCR to measure the differential infectivity of HA variants in human infection models using A/Wisconsin/67/2005.” Dr. Nicolas Noulin, Principal Virologist (Publication/Poster Board Number: LBP-34)
“Influenza haemagglutination inhibition assay: improving robustness and reproducibility is important in the screening of volunteers into a Human Viral Challenge Study.” Dr. Nicolas Noulin, Principal Virologist (Publication/Poster Board Number: LBP-32)
In addition to the poster presentations, event delegates can find out more about hVIVO’s pioneering platform, and how it can accelerate drug development, by visiting the hVIVO booth display, stand number 423, where visitors can meet with the hVIVO Business Development team and/or presenters Dr. Anthony Gilbert and Dr. Nicholas Noulin.
Commenting on August’s Options IX event, Dr. Anthony Gilbert, hVIVO Medical Director said “Options for the Control of Influenza is the largest scientific conference exclusively devoted to influenza. We are delighted to share our insights and extensive experience from hVIVO’s pioneering work conducting human challenge studies to accelerate drug and vaccine development. My colleagues and I are looking forward to participating in, and contributing to, this unique conference.”
If you would like to make contact with the hVIVO presenters, Dr. Gilbert or Dr. Noulin, or our business development team members before or during the Chicago event, please complete the contact form below.
Note to editors:
hVIVO plc (“hVIVO”) is a life sciences company pioneering a technology platform of human disease models to accelerate drug development and discovery in respiratory and infectious diseases. Based in the UK, hVIVO has conducted over 45 clinical studies, involving more than 2200 volunteers for a range of leading industry, governmental and academic clients.
The organisation was renamed from Retroscreen Virology to hVIVO in April 2015.
Find out more at hvivo.com